CCRAN Hosts Third Annual Pan-Tumour Biomarkers Conference 2025

TORONTO, June 12, 2025 /CNW/ - The Colorectal Cancer Resource & Action Network (CCRAN) has announced its third annual Pan-Tumour Biomarkers Conference, set to take place virtually on June 19-20, 2025. This event is poised to be a pivotal gathering as comprehensive genomic profiling (CGP) and biomarker-driven therapies become increasingly central to cancer treatment.

The conference arrives at a critical juncture for Canada's healthcare landscape, where provinces and territories are striving to synchronize clinical innovation with healthcare delivery. This year's agenda promises to explore the necessary steps for integrating CGP into cancer care, focusing on consistency, efficiency, and long-term sustainability.

According to Filomena Servidio-Italiano, President & CEO of CCRAN, "Precision oncology must be accessible to every Canadian metastatic cancer patient, regardless of geography or circumstance." The conference aims to mobilize the expertise and momentum required to address existing barriers in the cancer care system and to advance genomic testing's role in treatment.

A standout feature of this year's conference will be the keynote presentation from the Conference Board of Canada. During this presentation, a groundbreaking cost-benefit analysis will be revealed, showcasing the transformative potential of CGP across five types of tumors: lung, colorectal, breast, pancreatic, and prostate. This analysis is anticipated to highlight not only the substantial return on investment in modernizing Canada’s testing landscape but also the significant benefits for patients, such as improved survival rates, enhanced quality of life, and reduced treatment toxicity.

The conference is designed to attract a diverse audience, including healthcare professionals, health system administrators, researchers, policy leaders, patients, and caregivers. It aims to foster dialogue and collaboration among stakeholders committed to advancing equitable access to precision medicine in Canada.

CCRAN extends its thanks to its premier partners, including Merck, AstraZeneca, Roche, and Johnson & Johnson, for their dedication to improving access to precision oncology. Moreover, the organization acknowledges the crucial contributions from various sponsors and patient advocacy groups that ensure the patient perspective remains at the forefront of discussions.

Registration for the conference is free, and all sessions will be hosted virtually, with recordings available for post-event viewing. Interested participants can register and view the full agenda at www.ccran.org/biomarkers-conference.

The role of biomarker testing and precision medicine in cancer care is more critical than ever. As CCRAN continues to advocate for the integration of these innovations, the upcoming conference is expected to be a significant step forward in transforming the landscape of cancer treatment in Canada.